Treatment with dupilumab is safe and effective for patients with bullous pemphigoid, with complete remission seen as early as 4 weeks of treatment.

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Investment analysts at StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research report issued to clients and investors on Tuesday. The ...

Progression-free survival was improved among patients who received nivolumab and ipilimumab, and toxicity was generally greater among patients who received chemotherapy.